Ogoina Dimie, Finomo Finomo, Harry Tubonye, Inatimi Otonyo, Ebuenyi Ikenna, Tariladei Wolo-wolo, Afolayan Abimbola Anne
Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa state, Nigeria.
Department of Medicine, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.
PLoS One. 2015 May 1;10(5):e0125665. doi: 10.1371/journal.pone.0125665. eCollection 2015.
Based on growing evidence mainly from countries outside Sub-Saharan Africa, the World Health Organisation (WHO) now recommends initiation of antiretroviral therapy (ART) in HIV-infected individuals in developing countries when CD4 cell count (CD4+) is ≤ 500 cells/ul. Nigeria accounts for about 14% of the estimated HIV/AIDS burden in Sub-Saharan Africa. We evaluated the factors associated with timing of initiation of ART among treatment-ineligible HIV-infected adults from Nigeria.
We retrospectively reviewed the hospital records of ART ineligible HIV-infected adults who enrolled into HIV care between January 2008 and December 2012 at two major tertiary hospitals in Bayelsa State, South-South Nigeria. Demographic, clinical and laboratories data were obtained at presentation, at each subsequent visit at 6 monthly intervals and at time of initiation of ART. Cox proportional regression and Kaplan-Meier survival analysis were used to evaluate independent predictors of time to initiation of ART.
Amongst the 280 study participants, 70.6% were females, 62.6% had CD4+ ≥500 cells/ul, 48.4% had WHO HIV Stage 1 disease and 34.3% were lost to follow up. In a cohort of 180 participants followed up for ≥3 months, participants with CD4+ of 351-500 cells/ul and stage 2 disease were more likely to start ART earlier than those with CD4+ > 500 cells/ul (Hazard ratio [HR]-1.7, 95% confidence interval [CI] of 1.0-2.9) and stage 1 disease (HR-2.3 (95% CI-1.3-4.2) respectively. HIV-infected adults with faster CD4+ decay required earlier ART initiation, especially in the first year of follow up.
ART-ineligible HIV-infected adults on follow up in South-South Nigeria are more likely to require earlier initiation of ART if they have stage 2 HIV disease or CD4+ ≤500 cells/ul at presentation. Our findings suggest faster progression of HIV-disease in these groups of individuals and corroborate the growing evidence in support for earlier initiation of ART.
基于主要来自撒哈拉以南非洲以外国家的越来越多的证据,世界卫生组织(WHO)现在建议,在发展中国家,当艾滋病毒感染者的CD4细胞计数(CD4+)≤500个细胞/微升时,应开始抗逆转录病毒治疗(ART)。尼日利亚约占撒哈拉以南非洲估计的艾滋病毒/艾滋病负担的14%。我们评估了尼日利亚不符合治疗条件的艾滋病毒感染成年人中与开始抗逆转录病毒治疗时间相关的因素。
我们回顾性审查了2008年1月至2012年12月期间在尼日利亚南南地区巴耶尔萨州的两家主要三级医院登记接受艾滋病毒护理的不符合抗逆转录病毒治疗条件的艾滋病毒感染成年人的医院记录。在就诊时、随后每6个月的每次随访时以及开始抗逆转录病毒治疗时获取人口统计学、临床和实验室数据。使用Cox比例回归和Kaplan-Meier生存分析来评估开始抗逆转录病毒治疗时间的独立预测因素。
在280名研究参与者中,70.6%为女性;62.6%的CD4+≥500个细胞/微升;48.4%患有世界卫生组织艾滋病毒1期疾病;34.3%失访。在180名随访≥3个月的参与者队列中,CD4+为351 - 500个细胞/微升且患有2期疾病的参与者比CD4+>500个细胞/微升(风险比[HR]-1.7,95%置信区间[CI]为1.0 - 2.9)和患有1期疾病(HR-2.3(95%CI-1.3 - 4.2))的参与者更有可能更早开始抗逆转录病毒治疗。CD4+衰减更快的艾滋病毒感染成年人需要更早开始抗逆转录病毒治疗,尤其是在随访的第一年。
在尼日利亚南南地区接受随访的不符合抗逆转录病毒治疗条件的艾滋病毒感染成年人,如果在就诊时患有2期艾滋病毒疾病或CD4+≤500个细胞/微升,则更有可能需要更早开始抗逆转录病毒治疗。我们的研究结果表明这些人群中艾滋病毒疾病进展更快,并证实了支持更早开始抗逆转录病毒治疗的越来越多的证据。